Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
2023 · Nature Medicine · 113 citations
https://doi.org/10.1038/s41591-023-02568-1
T
Tomi Jun
Nihon University(JP)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
142
Papers
1.9K
Citations
24
h-index
43
i10-index
Tomi Jun is an academic researcher from Nihon University. The author has contributed to research in topics: Cancer Genomics and Diagnostics & Cancer Immunotherapy and Biomarkers & PARP inhibition in cancer therapy. The author has an h-index of 24, co-authored 121 publications.
ORCID: 0000-0002-2120-1704Papers by this author
worksAnalysis of sex-specific risk factors and clinical outcomes in COVID-19
2021 · Communications Medicine · 46 citations
https://doi.org/10.1038/s43856-021-00006-2
Diverse immune response of DNA damage repair-deficient tumors
2021 · Cell Reports Medicine · 42 citations
https://doi.org/10.1016/j.xcrm.2021.100276
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer
2021 · Prostate Cancer and Prostatic Diseases · 29 citations
https://doi.org/10.1038/s41391-021-00433-1
Prediction of individual COVID-19 diagnosis using baseline demographics and lab data
2021 · Scientific Reports · 11 citations
https://doi.org/10.1038/s41598-021-93126-7
Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis
2022 · Discover Oncology · 11 citations
https://doi.org/10.1007/s12672-022-00538-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat